Literature DB >> 19822392

Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A(1) adenosine receptors.

Masaru Saito1, Takahiro Yaguchi, Yoshiyuki Yasuda, Takashi Nakano, Tomoyuki Nishizaki.   

Abstract

Extracellular adenosine-induced apoptosis of CW2 human colonic cancer cells by activating caspase-3, -8 and -9, and the effect was enhanced by adding EHNA, an adenosine deaminase inhibitor. Adenosine-induced CW2 cell death was inhibited by 8-CPT, an A(1) adenosine receptor inhibitor, but otherwise 2-chloroadenosine, an A(1) adenosine receptor agonist, and MDL-12330A, an inhibitor of adenylate cyclase, mimicked the adenosine effect. For mice inoculated with CW2 cells, intraperitoneal injection with adenosine reduced tumor growth and more prominent reduction was obtained with co-injection with EHNA. Adenosine, thus, suppresses CW2 human colonic cancer growth by inducing apoptosis as mediated via A(1) adenosine receptors. 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822392     DOI: 10.1016/j.canlet.2009.09.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  30 in total

1.  Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway.

Authors:  Mahmoud Aghaei; Mojtaba Panjehpour; Fatemeh Karami-Tehrani; Siamak Salami
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-10       Impact factor: 4.553

Review 2.  Anticancer effect of adenosine on gastric cancer via diverse signaling pathways.

Authors:  Ayako Tsuchiya; Tomoyuki Nishizaki
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 3.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

4.  miR-378a-3p promotes differentiation and inhibits proliferation of myoblasts by targeting HDAC4 in skeletal muscle development.

Authors:  Xuefeng Wei; Hui Li; Bowen Zhang; Caixia Li; Dong Dong; Xianyong Lan; Yongzhen Huang; Yueyu Bai; Fengpeng Lin; Xue Zhao; Hong Chen
Journal:  RNA Biol       Date:  2016-09-23       Impact factor: 4.652

5.  Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.

Authors:  Fabrícia Dietrich; Fabrício Figueiró; Eduardo Cremonese Filippi-Chiela; Angélica Regina Cappellari; Liliana Rockenbach; Alain Tremblay; Patrícia Boni de Paula; Rafael Roesler; Aroldo Braga Filho; Jean Sévigny; Fernanda Bueno Morrone; Ana Maria Oliveira Battastini
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-05       Impact factor: 4.553

6.  Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy.

Authors:  A Kalhan; B Gharibi; M Vazquez; B Jasani; J Neal; M Kidd; I M Modlin; R Pfragner; D A Rees; J Ham
Journal:  Purinergic Signal       Date:  2011-11-27       Impact factor: 3.765

Review 7.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

8.  Mitochondrial and caspase pathways are involved in the induction of apoptosis by IB-MECA in ovarian cancer cell lines.

Authors:  Hamideh Abedi; Mahmoud Aghaei; Mojtaba Panjehpour; Sima Hajiahmadi
Journal:  Tumour Biol       Date:  2014-08-06

9.  Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3.

Authors:  Saeid Shirali; Mahmoud Aghaei; Mahdi Shabani; Mojtaba Fathi; Majid Sohrabi; Marzieh Moeinifard
Journal:  Tumour Biol       Date:  2013-01-24

10.  Enhanced migration of breast and lung cancer cells deficient for cN-II and CD73 via COX-2/PGE2/AKT axis regulation.

Authors:  Octavia Cadassou; Muhammad-Zawwad Raza; Christelle Machon; Laura Gudefin; Célia Armanet; Kamel Chettab; Jérôme Guitton; Maria Grazia Tozzi; Charles Dumontet; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Cell Oncol (Dordr)       Date:  2020-09-24       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.